Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial

BackgroundThis is a subgroup analysis of Korean patients from a phase 3 clinical trial investigating the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin.MethodsThis multicenter, placebo-controlled, double-blind, parallel-group stu...

Full description

Bibliographic Details
Main Authors:	Kyung-Wan Min, Bon Jeong Ku, Ji-Hyun Lee, Min-Seon Kim, Kyu-Jeung Ahn, Moon-Kyu Lee, Satoshi Kokubo, Satoshi Yoshida, Hyun-Ji Cho, Bong-Soo Cha
Format:	Article
Language:	English
Published:	Korean Diabetes Association 2017-01-01
Series:	Diabetes & Metabolism Journal
Subjects:	Asia Diabetes mellitus, type 2 Ipragliflozin Korea Metformin Randomized controlled trial Sodium-glucose cotransporter 2 inhibitor
Online Access:	https://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-41-135.pdf

Similar Items

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study
by: Ikuro Matsuba, et al.
Published: (2020-09-01)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
by: Shuichi Nagashima, et al.
Published: (2020-09-01)

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
by: Miyake Teruki, et al.
Published: (2018-09-01)

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
by: Atsuo Tahara, et al.
Published: (2019-11-01)

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study
by: Kazuyuki Tobe, et al.
Published: (2019-09-01)

Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study)
by: Masaya Koshizaka, et al.
Published: (2021-02-01)

Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study)
by: Hiroshi Miura, et al.
Published: (2019-09-01)

Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
by: Yukihiro Bando, et al.
Published: (2016-12-01)

Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
by: T. S. Panevin, et al.
Published: (2020-06-01)

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
by: Atsushi Tanaka, et al.
Published: (2020-06-01)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
by: Eugene Han, et al.
Published: (2020-01-01)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
by: Shuai Ma, et al.
Published: (2017-06-01)

Drug-induced Liver Injury Caused by Ipragliflozin Administration with Causality Established by a Positive Lymphocyte Transformation Test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A Case Report
by: Katsura Niijima, et al.
Published: (2017-03-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
by: Atsushi Tanaka, et al.
Published: (2021-07-01)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
by: Kiyohiko Takahashi, et al.
Published: (2019-03-01)

The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes
by: Hyun Hee Chung, et al.
Published: (2013-04-01)

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
by: Hideka Inoue, et al.
Published: (2019-07-01)

Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction
by: Celestino Sardu, et al.
Published: (2021-07-01)

Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
by: Tae Jung Oh, et al.
Published: (2019-06-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review
by: Hyun Kyu Ahn, et al.
Published: (2020-11-01)

Cancer Biology and Prevention in Diabetes
by: Swayam Prakash Srivastava, et al.
Published: (2020-06-01)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
by: Kohei Kaku, et al.
Published: (2020-05-01)

Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Ameliorates Nonalcoholic Fatty Liver Disease in Japanese Patients with Type 2 Diabetes Mellitus
by: Kanako Tashima, et al.
Published: (2019-05-01)

Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
by: Seung-Eun Lee, et al.
Published: (2019-08-01)

Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
by: Young Ki Lee, et al.
Published: (2013-12-01)

Metformin-Associated Lactic Acidosis: Predisposing Factors and Outcome
by: Min Ju Kim, et al.
Published: (2015-03-01)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
by: Kun Ho Yoon, et al.
Published: (2011-02-01)

Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by Metformin
by: Se-Kyeong Jang, et al.
Published: (2021-07-01)

Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in type 2 diabetes mellitus patients
by: Mansour Siavash, et al.
Published: (2017-01-01)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
by: Atsushi Tanaka, et al.
Published: (2021-09-01)

Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis
by: Parkyong Song, et al.
Published: (2021-02-01)

Spotlight on the Low dose Rosiglitazone/ Metformin Combination In Prevention of Type 2 Diabetes
by: Muhammad Abdul Hadi
Published: (2010-10-01)

A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients
by: Jeong-Eun Park, et al.
Published: (2018-06-01)

The Cross-talk Relationship between Metformin and Gut Microbiota
by: Hyder O. Mirghani. MD, et al.
Published: (2020-12-01)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
by: Odette S. Reifsnider, et al.
Published: (2020-12-01)

The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus
by: Chae Bin Lee, et al.
Published: (2021-03-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016-02-01)